It's adding insult to injury! JiangSu WuZhong Pharmaceutical Development is beset by three major Bearish factors. Will the agency rights for Tongyan needles change? | Quick Announcement
① JiangSu WuZhong Pharmaceutical Development is currently facing uncertainties such as allegations of violating information disclosure laws, subsidiary's alleged assistance in tax fraud, and changes in agency rights for AestheFill within China. ② Compared to the beginning of the year, the company's stock price has fallen over 35%, reaching a new low for this year.
JiangSu WuZhong Pharmaceutical Development is in trouble! A subsidiary has been sued for assisting in a tax fraud case and is also under investigation for violation of information disclosure regulations.
① JiangSu WuZhong Pharmaceutical Development announced that its subsidiary and the Chairman are being prosecuted for assisting in tax fraud of 0.242 billion yuan, and are also being investigated by the Securities Regulatory Commission for information disclosure violations, which may pose a risk of (Delisted); ② although the two incidents are closely timed, legal experts say that no correlation can be discerned at present; ③ since the third quarter of last year, JiangSu WuZhong's performance has shown significant improvement; ④ some investors have declared "they will protect their legitimate rights and interests" due to the significant fluctuations in stock prices.
JiangSu WuZhong Pharmaceutical Development is suspected of violations related to information disclosure and has been filed for investigation after years of losses, just turning a profit.|Brief Announcement
① JiangSu WuZhong Pharmaceutical Development has been put under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws; ② The company has reported a net income loss for six consecutive years, yet aims to turn a profit in 2024 by focusing on a single product in the medical aesthetics sector; ③ Previously, the company faced several instances of being penalized for various legal violations, but none have occurred in the last three years.
The photovoltaic film business is unlikely to turn a profit in the short term. Folai Ant New Energy Fund will suspend production | Quick read announcement.
① The photovoltaic film is currently facing intense price competition and a capacity adjustment period, so Fu Lai An Te new energy fund has decided to suspend production and operations to reduce losses; ② The decline in the selling price of the film products is greater than the decrease in unit costs, resulting in a further drop in the gross margin of the film products.
The launch of new medical beauty products contributed to performance, jiangsu wuzhong pharmaceutical development's net profit in the first three quarters increased by more than three times. | Interpretations
① In the first three quarters, jiangsu wuzhong pharmaceutical development's net profit attributable to the parent company increased by 311.54% year-on-year; ② The significant increase in performance during the reporting period of the AestheFill aesthetic facial filler contributed mainly to the company's performance growth; ③ The decline in the pharmaceutical sector business continues to expand.
Argus Research Initiates Coverage On Novo Nordisk With Buy Rating, Announces Price Target of $110